一季度药物市场激战:司美格鲁肽收入超80亿美元力压K药,预定“药王”桂冠

21财经网
May 07, 2025

21世纪经济报道记者季媛媛 上海报道凭借其明星产品GLP-1药物,诺和诺德与礼来在2025年第一季度继续展现了强劲的业绩增长态势。5月7日,诺和诺德公布2025年一季度业绩,总营收780.87亿丹麦克朗(约112.16亿美元),同比增长18%;研发投入103.08亿丹麦克朗(约14.81亿美元),同比增长19%。按地域分布来看,2025年一季度,美国市场收入443.16亿丹麦克朗(约63.65...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10